Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
coadministered cagrilintide and semaglutide in adults with overweight or obesity (phase 3, ~22.7% weight change at 68 weeks)
For context: the SELECT trial showed that subcutaneous semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events by 20% in adults with established cardiovascular disease and overweight or obesity but without diabetes (Lincoff AM et al., 2023, New England Journal of Medicine , doi:10.1056/NEJMoa2307563 PMID 37952131)
Zepbound is the trade name for tirzepatide when used to manage the weight of adults with obesity (BMI 30) or overweight (BMI 27) in the presence of an additional health condition
Between February and March 2026, the FDA issued warning letters to more than 30 telehealth companies for misleading marketing of compounded GLP-1 products
